The investment trust reported a substantial loss, suspended dividends, and saw its net asset value per share plummet. Economic uncertainties and poor performance of key investments have significantly impacted the company's financial health.
The investment trust reported a profitable year, with net assets increasing by 31.9% after paying dividends. The company's largest investment, Geron Corporation, received FDA approval for its oncology drug, a significant milestone.
Investment trust reports strong profit growth, despite revenue decline. Maintains dividend and positive outlook, but faces economic uncertainty.
Asset management firm announces new Company Secretary, with no major business impact.
Investment trust navigates volatility